• New Biomarker Offers Hope of Detecting Alzheimer's in Asymptomatic Stages

    Jun 12 | Diagnostics World | Until recently, all the available therapeutic options for treating Alzheimer’s disease were designed to reduce symptoms rather than address causes of the disease. But with two beta-amyloid antibodies now approved by the U.S. Food and Drug Administration, and tau-targeting agents in clinical trials, hopes are rising that Alzheimer’s progression can be delayed if not stopped. More
  • Sarcoidosis Test Aims to Speed, Simplify Diagnostic Process

    Jun 11 | Diagnostics World | Sarcoidosis is difficult to diagnose for a variety of reasons. For one, it is not limited to a single area or part of the body. Although the vast majority of people living with sarcoidosis have it in their lungs, it can also appear in the eyes, the skin, brain, heart, spinal cord, liver, kidney, and even in the bones. More
  • Blood Test Could Improve Diagnosis of Severe Strokes on a Global Scale

    Jun 06 | Diagnostics World | A potentially game-changing diagnostic assay is under development that can quickly and accurately identify who is and isn’t having a large vessel occlusion (LVO), a devastating subset of ischemic stroke that occurs when a major artery in the brain is blocked. More
  • Illumina Announces June 24, 2024 Spin-Off of GRAIL

    Jun 03 | Diagnostics World News | Late today, Illumina announced that its Board of Directors has approved the spin-off of GRAIL. GRAIL is anticipated to spin off from Illumina on June 24, 2024, and has applied to list on Nasdaq as "GRAL." More
  • Digital & AI Pathology Implementation: Making Informed Decisions on the Road to Adoption

    May 31 | Diagnostics World | After decades of false starts, digital pathology adoption is finally happening. Pathologists in these labs don’t have glass slides anywhere in their offices and have completely adapted their workflow and mindset to a digital world. They experience ‘faster than glass’ workflow advantages and tangible benefits associated with AI tools, but also have learned important lessons along the path to adoption. More
  • Quest Diagnostics, PathAI Team Up, PacBio Selected To Support Rare Disease Program, New Product from FoundationOne; More

    May 29 | Diagnostics World | Quest Diagnostics and PathAI announced a multi-faceted collaboration designed to accelerate the adoption of digital and AI pathology innovations; Ambry Genetics and PacBio were selected to support the Pediatric Mendelian Genomics Research Center (MGRC) program; Foundation Medicine launches FoundationOne RNA; more. More
  • Follow the Money: Karius Expansion, PinkDx Addresses Women’s Unmet Needs, POC Lyme Test, More

    May 28 | Diagnostics World | Karius plans extend its reach beyond the 400 U.S. hospitals currently using the Karius Test, an infectious disease diagnostic test that utilizes genomic analysis and artificial intelligence to detect over 1,000 pathogens from a single blood sample; PinkDx launches to pursue its vision of identifying unmet medical needs that are unique to women; En Carta develops a point-of-care diagnostic for Lyme disease; more. More
  • AI System For Diagnosing Rare Diseases and Solving Medical Cold Cases

    May 23 | Diagnostics World | Using an artificial intelligence (AI) model that was trained on millions of variants from identified genetic disorders and incorporates the complex decision-making process of human molecular scientists, investigators at Baylor College of Medicine are on track to automate the diagnosis of an enormous number of undiagnosed conditions. More
  • Clinical Trial Underway for New-and-Improved Prostate Cancer Test

    May 21 | Diagnostics World | Researchers at the University of Michigan (U-M) have developed a urine test for prostate cancer known as MyProstateScore 2.0 (MPS2), now a property of spinoff LynxDx, which they expect to significantly improve upon the performance of existing assays by focusing on clinically significant cancers and capturing more biomarkers in a single test. More
  • 3D Printing Could Make Mass Spectrometry Local

    May 16 | Diagnostics World | Science and technology have moved up the appearance of a high-performance point-of-care mass spectrometer to a near-term possibility, which would make it both cheaper and more convenient to monitor chronic health conditions from just about anywhere a 3D printer could be deployed—including the jungle, Antarctica, and future colonies on Mars. More
View more articles

 
DXX-Industry-spotlight

merck


Custom Diagnostic Antibody Development & Manufacturing Services

Overcome Process Challenges by outsourcing your custom antibody production to us. How partnering with an antibody production expert can improve your assay, accelerate launch, and maintain your manufacturing.

Learn more